RenovoRx Data Shows 51% Local Drug Extraction in Pancreatic Cancer Trial
Event summary
- RenovoRx published PK/PD data from its Phase III TIGeR-PaC trial showing 51% local drug extraction in pancreatic cancer patients.
- Intra-arterial gemcitabine (IAG) reduced systemic exposure by 50% compared to intravenous delivery.
- Statistically significant correlation observed between drug metabolite levels and tumor marker reduction.
- TIGeR-PaC trial enrollment completed in August 2026 with topline data expected in late 2027.
The big picture
This data supports RenovoRx's differentiated approach to pancreatic cancer treatment, aligning with the broader industry shift toward targeted therapies that minimize systemic toxicity. The results position RenovoRx as a potential disruptor in oncology drug delivery, though commercial success will depend on successful trial completion and effective device adoption strategies. The company's $1.1 million in 2025 RenovoCath sales suggests early traction, but scaling will be critical for long-term viability.
What we're watching
- Clinical Validation
- Whether the Phase III trial results will confirm the targeted delivery benefits observed in this sub-study.
- Regulatory Pathway
- The pace at which RenovoRx can secure FDA approval for its drug-device combination product.
- Commercialization Strategy
- How RenovoRx will scale RenovoCath adoption beyond current $1.1 million annual revenue.
Related topics